Pa. Jury Urged To Punish J&J For Pushing Risperdal On Kids

Law360, Philadelphia (September 17, 2019, 7:04 PM EDT) -- An attorney for a man who grew breasts after using the antipsychotic medication Risperdal as a young boy tasked a Philadelphia jury on Tuesday with punishing Johnson & Johnson for what he said was the company’s reckless decision to surreptitiously push the drug on children despite its risks.

Jason Itkin, an attorney with Arnold & Itkin LLP representing Nicholas Murray, told jurors during opening arguments that J&J subsidiary Janssen Pharmaceuticals Inc. had promoted Risperdal off-label even as evidence mounted internally that the powerful antipsychotic medication could lead to hormone imbalances linked to abnormal breast growth.

Murray has already been awarded $1.75...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS